ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Diabetes therapy (43 abstracts)
Dapagliflozin after liraglutide in patients with type 2 diabetes
Paloma Moreno-Moreno , Concepción Muñoz-Jiménez , María Rosa Alhambra-Expósito & María Ángeles Gálvez-Moreno
Hospital Universitario Reina Sofía, Córdoba, Spain.
Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.
Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatment change: age, sex, time of diabetes evolution, Body mass index (BMI), abdominal perimeter (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL, HDL, triglycerides (TG), uric acid (UA). Statistical analysis: comparing means with Student’s test.
Results: 15 patients with DM-2 treated with metformin 1000 mg/12 h and liraglutide 1.8 mg with optimal glycemic control and stabilized weight loss. 60% women Age: 56±7.5 years. Time of diabetes evolution: 8±4.1 years. Weight loss achieved 6 months after the change of treatment was 9.7±11 Kg. No side effects were recorded. The treatment change was satisfactory for all patients.
| Basal (mean ± SD) | 6 months (mean ± SD) | P | |
| Weight (Kg) | 96.3±11 | 89.5±11 | 0.1 |
| BMI (kg/m2) | 34±2.7 | 31.5±2.8 | 0.02 |
| BP (cm) | 109.5±9.5 | 105.3±9 | 0.2 |
| SBP (mmHg) | 137.6±10.5 | 130.3±9 | 0.05 |
| DBP (mmHg) | 86.6±14.5 | 72.8±8.1 | 0.003 |
| HbA1c (%) | 7±0.2 | 6.5±0.3 | 0.001 |
| LDL (mg/dl) | 95±115.7 | 80.5±11.6 | 0.01 |
| HDL (mg/dl) | 45.3±7.4 | 48.6±4.8 | 0.2 |
| TG (mg/dl) | 178.6±69.8 | 124.6±37.3 | 0.01 |
| UA (mg/dl) | 7.1±0.8 | 6.3±1.1 | 0.002 |
Conclusions: The change of treatment of liraglutide 1.8 mg to dapagliflozin in patients with optimal glycemic control and stabilization weight loss, achieves a progression in weight loss and improves the metabolic control of the patient with DM-2. The change of treatment was satisfactory for all patients.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more